Gossamer Bio Inc. (GOSS)
Gossamer Bio Inc. (GOSS) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | n/a |
| Revenue (ttm) | 53.29M |
| Net Income (ttm) | -125.22M |
| Beta | n/a |
| EPS (ttm) | n/a |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.87 |
| P/B (ttm) | -0.23 |
| P/S (ttm) | 1.44 |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | NaN |
| Avg. Volume (20D) | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a - n/a |
| 52-Week Range | n/a - n/a |
| Analyst | Buy |
| Price Target | 1 (NaN%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It ha...
Financial Performance
In 2025, Gossamer Bio's revenue was 48.47M, a decrease of -57.74% compared to the previous year's 114.7M. Earnings were -170.37M, an increase of 201.39%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for GOSS stock is "Buy". The 12-month stock price forecast is 1, which is downside of NaN% from the latest price.
Stock Forecasts